Specifically, FAT1 inhibits the proliferation of DLBCL cells by increasing m6A modification and decreasing YAP1 expression via the TGFβ-smad2/3-ALKBH5 pathway (Fig. 4E). The gene discussed is FAT1; the disease is diffuse large B-cell lymphoma.